Pharmacokinetics
Selank Half Life and Pharmacokinetics
Why the intact peptide is short-lived, what its metabolites may add, and how poorly the human numbers are characterized.
In plain English
The Selank half life — the time it takes for half of the peptide to clear the body — is short, on the order of minutes for the intact molecule. That sounds like a problem for something meant to calm anxiety, but there is a twist: when Selank breaks down, the pieces it leaves behind (its metabolites) appear to stay active, so the effect may last longer than the raw half-life suggests. The designers also built the molecule to resist breakdown longer than the natural peptide it came from. One honest caveat: solid human pharmacokinetic data — careful measurements of how Selank rises and falls in people — barely exists in mainstream Western science. So the half-life picture is reasonable and mechanism-based, but not nailed down by rigorous human studies.
The intact peptide is short-lived
The intact Selank heptapeptide is rapidly metabolized, with a reported plasma half-life on the order of minutes. This rapid clearance is typical of small peptides, which circulating peptidases break down quickly. It is also consistent with a recurring user observation — that the noticeable per-dose effect is brief, often estimated at a few hours — though that anecdotal timing is not the same as a measured pharmacokinetic curve and is discussed on Selank effects. The short intact half-life is the starting point for understanding how Selank behaves, not the whole story.
Active metabolites and the design rationale
Selank's metabolites are proposed to retain biological activity, which would extend the functional duration of effect beyond what the intact peptide's half-life implies — a recurring rationale in the literature for why a minutes-long half-life can still produce a usable anxiolytic window [2]. The molecule's stability is by design: the C-terminal Pro-Gly-Pro extension dramatically slows enzymatic degradation relative to native tuftsin, which is the core reason Selank was engineered from tuftsin in the first place [13]. The enkephalinase-inhibition mechanism adds another layer — by slowing the breakdown of endogenous enkephalins, Selank's downstream effect can outlast its own presence [2].
Why the human numbers are uncertain
Pharmacokinetics of intact Selank in humans are poorly characterized in mainstream Western literature. The active-metabolite rationale for a prolonged effect is mechanistically plausible but not rigorously quantified in Western sources, and no validated human PK profile is published outside the limited Russian research tradition. This uncertainty is one of the honest gaps in the Selank record: the qualitative story (short intact half-life, longer functional effect via metabolites) is coherent, but the precise human numbers — peak concentration, area under the curve, true effect duration — are not established. Treat half-life statements as approximate and mechanism-derived, not as validated clinical pharmacokinetics.
What the half-life implies for the route studied
The short intact half-life helps explain why the intranasal route dominates the clinical literature: nasal delivery is practical for a peptide that survives poorly and acts briefly, and it underpinned the 0.15% clinical formulation used in Russian anxiety studies [5]. Rodent pharmacokinetic work used intravenous and other routes to characterize clearance. None of this constitutes a dosing schedule — for how the compound was administered in studies, see Selank dosage; the half-life data here simply describes the time course researchers worked with.